Kristin Richeimer
Heather Wakelee, MD
Welcome Letter
Dear Colleagues and Friends, Welcome to the 2021 IASLC Annual Report! As we look back on 2021, we see how our lives, our Association and the lung cancer community as a whole continued to be impacted by the pandemic. While we hoped that 2021 would bring us back together to meet in person, that was not to be. However, IASLC was able to produce extraordinary publications and education offerings within a virtual platform.
IASLC Year in Review
Dr. Heather Wakelee welcomes you to the IASLC 2021 Annual Report.
IASLC's International and Multidisciplinary Membership
Despite the worldwide focus on COVID-19, IASLC members from all corners of the world continued to drive scientific advancements and collaboration. IASLC members worked in incredibly difficult circumstances during the pandemic. Furthering the mission of the IASLC, members were supported in these global efforts by receiving discounted registration fees to meetings and educational events, complimentary access to the Journal of Thoracic Oncology and discounted publication fees for the open-access IASLC Journal, JTO Clinical and Research Reports. (JTO CRR)
Members By Country/Region
Members by Primary Specialty
| Labels | Values |
|---|---|
| Medical Oncology | 1984 |
| Thoracic Surgery | 862 |
| Other/Unknown | 613 |
| Pulmonary Medicine | 593 |
| Cancer Research | 412 |
| Radiation Oncology | 389 |
| Pathology | 335 |
| Advocacy | 270 |
| Biotech/Pharmaceutical | 170 |
| Nursing | 93 |
| Diagnostic Radiology | 90 |
| Pharmacy | 51 |
| Biostatistics | 40 |
| Smoking Cessation | 11 |
| Hemotology | 8 |
| Resp Therapy/Physiotherapy | 6 |
donut
Professional Activity/Practice
| Labels | Values |
|---|---|
| Academic Medical Center | 2966 |
| Other/Unknown | 830 |
| Cancer Center | 655 |
| Pharmaceutical/Biotech | 554 |
| Private Practice (Hospital) | 216 |
| Private Practice (Office) | 202 |
| Training Program | 147 |
| Non-Profit or Advocacy | 115 |
| Laboratory Research | 101 |
| Government Agency | 83 |
| Administration | 33 |
| Retired | 25 |
donut
Committees
Serving on an IASLC committee in a volunteer capacity, members contribute their specialized skills and talents to help define the work of the organization, develop educational content, shape the association's messaging, plan annual meetings, contribute to publications authored by the IASLC, and more.
Membership Committee
Led by Dr. Nan Wu of Peking University Cancer Hospital & Institute in China, this committee emphasizes the benefits that make the IASLC a great value for thoracic oncology professionals and fosters relationships with new members from around the globe.
Mesothelioma Committee
Dr. Paul Bass of the Netherlands Cancer Institute is the new Chair of the Mesothelioma Committee. This Passionate group is driven to accelerate the pace of research and work across geographies to develop strategic research goals and to bring the disease to the forefront of research. In recent years, the have been several research updates in mesothelioma-many of which were spearheaded by members of this committee.
Nurses and Allied Health Professional Committee
Chaired by Dr. Maria Ftanou of Peter MacCallum Cancer Center in Australia, this committee is comprised of members of the multidisciplinary team, including: clinical nurse specialists, dieticians and nutritionists, lung cancer nurse specialists, nurse navigators, occupational therapists, palliative care nurses, pharmacists, physician assistants, physiotherapists, radiation oncology nurses, respiratory therapists, psychologists, social workers, speech and language therapists, surgical nursing specialists, and others.
Patient Advocacy Committee
The IASLC and the Patient Advocacy Committee, welcomes Chair, Jill Feldman of the U.S.-Based EGFR Resisters. Jill is committed to diversity and equity and plans to guide the committee to improve the global reach of the IASLC. This committee addresses the direct impact research has on its beneficiaries; patients with lung cancer, and how they can support continued research to improve treatment options and availability.
Screening and Early Detection Committee
The IASLC Screening and Early Detection Committee advance screening and early detection programs through education and research across the globe. Led by Dr. Stephen Lam of the BC Cancer Center in Canada, this multidisciplinary group is composed of leaders from radiology, thoracic surgery, pulmonary medicine, medical oncology, nursing, basic science, and advocacy organizations from North America, Europe, Asia, South America, and Africa.
Staging and Prognostic Factors Committee
Staging lung cancer and other thoracic malignancies accurately is critical in deciding treatment regimens and ensuring the best standardized care for patients worldwide. The IASLC's Staging & Prognostic Factors Committee, chaired by Dr. Hisao Asamura, of Keio University School of Medicine in Japan, actively works to study and improve the current staging system for lung cancer, as well as for thymic, esophageal cancers and mesothelioma.
Committee Chair:
Celine Mascaux
The Basic and Translational Science Committee is aimed at tackling key scientific questions to advance the understanding of thoracic malignancies. The committee brings together leading scientists, researchers, and clinicians from around the world to collaborate, share knowledge, and drive progress in the field of thoracic oncology.
Committee Chair:
Jarushka Naidoo
The Communications Committee develops campaigns to increase IASLC brand recognition and credibility while educating the public about complex lung and thoracic cancer issues. The committee also reviews articles for publication in the Journal of Thoracic Oncology and determines which pieces to promote to the media.
Committee Chair:
Nir Peled
The Global Multidisciplinary Practice Standards Committee (GMPSC) is dedicated to the development and implementation of global standards for tobacco control, screening, diagnosis, treatment, and supportive care management of thoracic malignancies. Comprised of a diverse group of internationally renowned experts in the field of thoracic oncology, including medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, and ancillary care experts and patient advocates. The GMPSC aims to establish comprehensive, multidisciplinary, evidence-based global standard(s) by reviewing literature and existing guidelines from around the world. By providing global standards, countries, and health systems will have a clear path forward to ensure optimal quality outcomes can be achieved.
Committee Chair:
Sudish Murthy
The Membership Committee review and recommend membership status requirements and benefits for all IASLC members. Members of this committee also strategize and implement tactics to increase and retain association membership in their area of specialty and region.
Committee Chair:
Michelle Turner
The Nursing & Allied Health Professionals Committee (NAHP) within IASLC is comprised of multidisciplinary clinicians and researchers each with a unique perspective, committed to advancing the education of both practitioners and patients in thoracic oncology. Our goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship and end of life.
Committee Chair:
Shani Shilo
The Patient Advocates Committee ensures that the IASLC addresses the informational needs of the public, advocates and patients living with lung and thoracic cancers. This committee also comprehensively addresses the educational and related needs of the public as an important constituency in the work of the association. The IASLC, and this committee especially, works to ensure that the patient's voice and needs are not overshadowed by the science behind daily patient care.
Committee Chair:
Annette McWilliams
The Screening and Early Detection Committee provides leadership and oversight of IASLC activities in these areas. The committee works with appropriate internal committees to enhance the quality and quantity of IASLC cancer prevention initiatives and provides leadership in partnership with other societies in the area of cancer prevention and screening.
Committee Chair:
Tindara Franchina
The Career Development Committee is dedicated to fostering and advancing careers across the professional continuum by providing diverse opportunities in research, education, clinical care, and leadership in the field of thoracic malignancies worldwide. The committee will include representation from early career to established investigators.
Committee Chair:
Pranshu Mohindra
The Education Committee plans and implements educational activities in accordance with IASLC’s mission of providing education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
Committee Chair:
Andreas Charalambous
The Global Policy and Partnerships Committee is focused on conquering thoracic cancers worldwide through policy change. Comprising global experts and professionals in the field of thoracic oncology, this committee is dedicated to advancing policy initiatives and enacting evidence-based recommendations to improve the prevention, diagnosis, and treatment of thoracic malignancies worldwide.
Committee Chair:
Tom Stinchcombe
The Multidisciplinary Clinical Science Committee at the IASLC comprises leading experts and researchers in the field of clinical thoracic oncology who will tackle key scientific questions in the diagnosis, treatment, and management of thoracic malignancies worldwide.
Committee Chair:
Sanja Dacic
For more than 35 years, the IASLC Pathology Committee has played a fundamental role in fulfilling core aspects of the association's mission.
Committee Chair:
Paul Baas
The Rare Tumors Committee is a specialized committee established to address the unique challenges and needs of patients and healthcare professionals dealing with rare thoracic malignancies worldwide.
Committee Chair:
Joelle Fathi
Improving patient care by raising awareness of cessation-related data and by provision of information regarding the latest and most successful cessation techniques for patients with lung cancer.
IASLC 2021 World Conference on Lung Cancer
The IASLC made an early decision to execute the 2021 World Conference on Lung Cancer (WCLC 2021) as a fully virtual event. The WCLC Conference Chairs, Drs. David Harpole, Thomas Stinchcombe, and Kristin Higgins continued the IASLC’s tradition of delivering high-quality educational programs marked by practice-changing abstracts.
WCLC 2021 Quick Facts
530
Featured & E-Posters / Posters
85
Invited Session Chairs
26
Plenary Speakers
29
Discussants
Media Coverage
28
News Releases Issued
135
Registered Journalists
34
Stories in Spanish Media Outlets
76
Stories in Asian Media Outlets
Journal of Thoracic Oncology
The Journal of Thoracic Oncology's (JTO) influence on the field is represented by its increased impact factor, which has climbed dramatically in recent years. The 2020 impact factor for JTO is 15.609 up from 13.357 in 2019. This moves the journal’s rank to 4th among 64 respiratory medicine journals and 13th among 242 oncology journals.
JTO Clinical and Research Reports
JTO Clinical and Research Reports (JTO CRR) transitioned to article-based publishing and became a monthly publication in 2021. In 2021, JTO CRR articles became indexed and available through PubMed Central.
JTO Impact Factor on the Rise
| Labels | Values |
|---|---|
| 2008 | 3.508 |
| 2009 | 4.547 |
| 2010 | 4.040 |
| 2011 | 3.661 |
| 2012 | 4.473 |
| 2013 | 5.8 |
| 2014 | 5.282 |
| 2015 | 5.040 |
| 2016 | 6.595 |
| 2017 | 10.336 |
| 2018 | 12.460 |
| 2019 | 13.357 |
| 2020 | 15.609 |
bar
It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 15.609, JTO is the leading journal in thoracic oncology and, in the top fifteen (ranked 14th) of all cancer journals,” said Editor-in-Chief, Dr. Alex A. Adjei, MD, Ph.D. “JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.
Patient Advocacy
The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the lung cancer community and to the organization.
2021 Cancer Care Team Awards
The 2021 IASLC Cancer Care Team Award recognizes extraordinary patient care in the field of thoracic malignancies. Awardees are nominated by patients and their loved ones.
Financials
| December 31 (Unaudited) | ||
|---|---|---|
| 2021 | 2020 | |
| Program Revenues | $12,78,644 | $7,148,662 |
| Membership Revenues | $744,497 | $632,870 |
| Other Revenues | $927,858 | -- |
| Total Revenues | $14,465,999 | $7,781,532 |
| Direct Program Expenses | $7,582,308 | $4,584,120 |
| G&A Expenses | $5,115,252 | $5,520,532 |
| Total Expenses | $12,697,560 | $10,104,652 |
| Operating Surplus(Deficit) | $1,759,439 | ($2,323,120) |
| Other Income/Expense | $950,000 | $65,296 |
Revenue by Type
| Labels | Values |
|---|---|
| Conferences & Meetings | 62% |
| Scientific Projects | 9% |
| Publications | 12% |
| Membership | 5% |
| Fellowships | 5% |
| Federal Grants | 6% |
donut
International Lung Cancer Foundation
Donation Sources
| Labels | Values |
|---|---|
| membership Renewals | 5% |
| Online Donations | 14% |
| Honoraria | 6% |
| Meetings (not WCLC) | 6% |
| WCLC | 21% |
| Adi Gazdar Estate | 48% |
donut
